2018
Endothelins in inflammatory neurological diseases
D'Orléans-Juste P, Akide Ndunge O, Desbiens L, Tanowitz HB, Desruisseaux MS. Endothelins in inflammatory neurological diseases. Pharmacology & Therapeutics 2018, 194: 145-160. PMID: 30291906, PMCID: PMC6348026, DOI: 10.1016/j.pharmthera.2018.10.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCentral nervous systemNeuroinflammatory processesCentral nervous system vasculitisNon-infectious inflammatory processesBlood-brain barrier levelEndothelin-1 antagonistsSynthesis of endothelinInflammatory neurological diseasesMediator/modulatorProgression of neurodegenerationPotent vasoactive compoundsNeuroinflammatory diseasesEndothelin pathwayEndothelin-1Inflammatory processClinical trialsVasoactive compoundsCardiovascular propertiesNervous systemAmino acid peptideNeurological diseasesEndothelial integrityEndothelinAlzheimer's diseaseNeurodegenerative disorders
2012
Cerebral Malaria We Have Come a Long Way
Shikani HJ, Freeman BD, Lisanti MP, Weiss LM, Tanowitz HB, Desruisseaux MS. Cerebral Malaria We Have Come a Long Way. American Journal Of Pathology 2012, 181: 1484-1492. PMID: 23021981, PMCID: PMC3483536, DOI: 10.1016/j.ajpath.2012.08.010.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCerebral malariaLong-term neurological sequelaeEffective antiparasitic treatmentNeurological sequelaeCerebral damageSerious complicationsPlasmodium infectionAntiparasitic treatmentSignificant burdenMalariaExperimental modelDevastating diseaseSub-Saharan AfricaComplicationsSequelaePathogenesisInfectionAmerican JournalDiseasePathologySurvivorsOriginal research